Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lessons from the hemodialysis (HEMO) study: An improved measure of the actual hemodialysis dose
Autore:
Depner, T; Beck, G; Daugirdas, J; Kusek, J; Eknoyan, G;
Indirizzi:
NIDDKD, Bethesda, MD 20892 USA NIDDKD Bethesda MD USA 20892NIDDKD, Bethesda, MD 20892 USA Cleveland Clin Fdn, Cleveland, OH 44195 USA Cleveland Clin Fdn Cleveland OH USA 44195 in Fdn, Cleveland, OH 44195 USA Univ Calif Davis, Davis, CA USA Univ Calif Davis Davis CA USAUniv Calif Davis, Davis, CA USA Univ Chicago, Chicago, IL 60637 USA Univ Chicago Chicago IL USA 60637Univ Chicago, Chicago, IL 60637 USA Baylor Coll Med, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 ylor Coll Med, Houston, TX 77030 USA
Titolo Testata:
AMERICAN JOURNAL OF KIDNEY DISEASES
fascicolo: 1, volume: 33, anno: 1999,
pagine: 142 - 149
SICI:
0272-6386(199901)33:1<142:LFTH(S>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
DIALYSIS; MORBIDITY; MORTALITY; PRESCRIPTION; EFFICIENCY; ADEQUACY;
Keywords:
hemodialysis; adequacy of hemodialysis; Kt/V; HEMO study; National Institutes of Health (NIH); National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK); clinical trial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Depner, T Div Nephrol, 4301 X St, Sacramento, CA 95817 USA Div Nephrol 4301 X St Sacramento CA USA 95817 ento, CA 95817 USA
Citazione:
T. Depner et al., "Lessons from the hemodialysis (HEMO) study: An improved measure of the actual hemodialysis dose", AM J KIDNEY, 33(1), 1999, pp. 142-149

Abstract

The Hemodialysis (HEMO) Study is a multicenter, prospective, randomized, 2x 2 factorial clinical trial designed to evaluate the efficacy of the doseof dialysis delivered ("standard" v "high") and dialysis membrane flux ("low" v "high") in reducing the morbidity and mortality of patients. The study is nearly half complete. Although both patients and investigators are blinded to the overall findings, which will not be available for another 3 years, important data have been generated from which a more accurate expression has been derived for the dose of dialysis received by each patient in thetrial. This new expression of the effectiveness of dialysis, eKt/V, is a two-pool approximation derived from the traditional single-pool Kt/V (spKt/V) and time on dialysis. The dialysis prescription for the HEMO Study subjects is individualized to achieve the target dose for each patient and is closely monitored by measuring the more accurate and validated expression of eKt/V. Comparisons of the HEMO Study dose of dialysis with other studies have been confused by this unique expression (eKt/V) of the dialysis dose and adequacy adopted for the HEMO Study. The target eKt/V dose in the "standard" arm of the Study Is 1.05 and in the "high" arm is 1.45 per dialysis thrice weekly. Based on data available from 426 subjects randomized to each arm,the target of 1.05 in the "standard" dose of the HEMO Study is equivalent to an spKt/V of 1.32, and that of the "high" dose, 1.67. Thus, volunteers in the "standard" arm of the Study are receiving a tightly controlled and closely monitored dose, which is above the current national mean spKt/V, and above that of the accepted minimum standard spKt/V of 1.2. When completed, the HEMO Study will show whether there are merits of a tightly controlled hemodialysis dose that is consistently delivered over a prolonged period andwhether a high dose Is beneficial and safe to prescribe. (C) 1999 by the National Kidney Foundation, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 13:46:17